These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 34337041)

  • 41. Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus.
    Liu S; Guo L; Li H; Zhang B; Sun J; Zhou C; Zhou J; Fan J; Ye Q
    Ann Surg Oncol; 2018 Jul; 25(7):2098-2104. PubMed ID: 29728879
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.
    Cai M; Liang L; Zhang J; Chen N; Huang W; Guo Y; Hong X; Lin L; Liu Y; Dan C; Deng H; Liu X; Zhou J; Chen Y; Chen H; Zhu K
    Int J Surg; 2024 Jun; ():. PubMed ID: 38869974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
    Nagamatsu H; Sumie S; Niizeki T; Tajiri N; Iwamoto H; Aino H; Nakano M; Shimose S; Satani M; Okamura S; Kuromatsu R; Matsugaki S; Kurogi J; Kajiwara M; Koga H; Torimura T
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):243-50. PubMed ID: 26754678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial.
    Guo L; Wei X; Feng S; Zhai J; Guo W; Shi J; Lau WY; Meng Y; Cheng S
    Hepatol Int; 2022 Dec; 16(6):1368-1378. PubMed ID: 36271176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reappraisal of Portal Vein Tumor Thrombosis as a Prognostic Factor for Patients with Hepatocellular Carcinoma.
    Chang Y; Yu SJ; Kim HC; Lee YB; Cho EJ; Lee JH; Kim YJ; Chung JW; Yoon JH
    Gut Liver; 2024 Jan; 18(1):156-164. PubMed ID: 38013475
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus.
    Ye JZ; Zhang YQ; Ye HH; Bai T; Ma L; Xiang BD; Li LQ
    World J Gastroenterol; 2014 Dec; 20(45):17141-7. PubMed ID: 25493028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
    Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
    Gorodetski B; Chapiro J; Schernthaner R; Duran R; Lin M; Lee H; Lenis D; Stuart EA; Nonyane BA; Pekurovsky V; Tamrazi A; Gebauer B; Schlachter T; Pawlik TM; Geschwind JF
    Eur Radiol; 2017 Feb; 27(2):526-535. PubMed ID: 27277261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
    Meng XC; Chen BH; Huang JJ; Huang WS; Cai MY; Zhou JW; Guo YJ; Zhu KS
    World J Gastroenterol; 2018 Jan; 24(4):484-493. PubMed ID: 29398869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
    Zhang ZH; Liu QX; Zhang W; Ma JQ; Wang JH; Luo JJ; Liu LX; Yan ZP
    World J Gastroenterol; 2017 Nov; 23(43):7735-7745. PubMed ID: 29209114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
    Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC
    Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis.
    Li S; Li L; Li B; Wang W
    Br J Radiol; 2020 Aug; 93(1112):20190279. PubMed ID: 32464068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang XP; Wang K; Li N; Zhong CQ; Wei XB; Cheng YQ; Gao YZ; Wang H; Cheng SQ
    BMC Cancer; 2017 Dec; 17(1):902. PubMed ID: 29282010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.
    Chen B; Dai H; Yang J; Zhang G; Wen C; Xiang X; Lin R; Huang Y
    Curr Cancer Drug Targets; 2023; 23(7):564-571. PubMed ID: 36790005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study.
    Yu JI; Park JW; Park HC; Yoon SM; Lim DH; Lee JH; Lee HC; Kim SW; Kim JH
    Radiother Oncol; 2016 Feb; 118(2):408-15. PubMed ID: 26830695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma.
    Lee JW; Hwang SH; Kim DY; Han KH; Yun M
    Clin Nucl Med; 2017 Jan; 42(1):e35-e40. PubMed ID: 27775940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization.
    Zhang B; Huang B; Yang F; Yang J; Kong M; Wang J; Xiang Y; Wang K; Peng R; Yang K; An C; Yan D
    J Hepatocell Carcinoma; 2024; 11():651-663. PubMed ID: 38559554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.